Cargando…

Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis

BACKGROUND: Emerging evidence revealed that gut microbial dysbiosis is implicated in the development of plasma cell dyscrasias and amyloid deposition diseases, but no data are available on the relationship between gut microbiota and immunoglobulin light chain (AL) amyloidosis. METHODS: To characteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Jipeng, Zhao, Jin, Ning, Xiaoxuan, Qin, Yunlong, Xing, Yan, Wang, Yuwei, Jia, Qing, Huang, Boyong, Ma, Rui, Lei, Changhui, Zhou, Meilan, Yu, Zixian, Zhang, Yumeng, Guo, Wei-Feng, Sun, Shiren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628213/
https://www.ncbi.nlm.nih.gov/pubmed/36341382
http://dx.doi.org/10.3389/fimmu.2022.973760
_version_ 1784823147253465088
author Yan, Jipeng
Zhao, Jin
Ning, Xiaoxuan
Qin, Yunlong
Xing, Yan
Wang, Yuwei
Jia, Qing
Huang, Boyong
Ma, Rui
Lei, Changhui
Zhou, Meilan
Yu, Zixian
Zhang, Yumeng
Guo, Wei-Feng
Sun, Shiren
author_facet Yan, Jipeng
Zhao, Jin
Ning, Xiaoxuan
Qin, Yunlong
Xing, Yan
Wang, Yuwei
Jia, Qing
Huang, Boyong
Ma, Rui
Lei, Changhui
Zhou, Meilan
Yu, Zixian
Zhang, Yumeng
Guo, Wei-Feng
Sun, Shiren
author_sort Yan, Jipeng
collection PubMed
description BACKGROUND: Emerging evidence revealed that gut microbial dysbiosis is implicated in the development of plasma cell dyscrasias and amyloid deposition diseases, but no data are available on the relationship between gut microbiota and immunoglobulin light chain (AL) amyloidosis. METHODS: To characterize the gut microbiota in patients with AL amyloidosis, we collected fecal samples from patients with AL amyloidosis (n=27) and age-, gender-, and BMI-matched healthy controls (n=27), and conducted 16S rRNA MiSeq sequencing and amplicon sequence variants (ASV)-based analysis. RESULTS: There were significant differences in gut microbial communities between the two groups. At the phylum level, the abundance of Actinobacteriota and Verrucomicrobiota was significantly higher, while Bacteroidota reduced remarkably in patients with AL amyloidosis. At the genus level, 17 genera, including Bifidobacterium, Akkermansia, and Streptococcus were enriched, while only 4 genera including Faecalibacterium, Tyzzerella, Pseudomonas, and Anaerostignum decreased evidently in patients with AL amyloidosis. Notably, 5 optimal ASV-based microbial markers were identified as the diagnostic model of AL amyloidosis and the AUC value of the train set and the test set was 0.8549 (95% CI 0.7310-0.9789) and 0.8025 (95% CI 0.5771-1), respectively. With a median follow-up of 19.0 months, further subgroup analysis also demonstrated some key gut microbial markers were related to disease severity, treatment response, and even prognosis of patients with AL amyloidosis. CONCLUSIONS: For the first time, we demonstrated the alterations of gut microbiota in AL amyloidosis and successfully established and validated the microbial-based diagnostic model, which boosted more studies about microbe-based strategies for diagnosis and treatment in patients with AL amyloidosis in the future.
format Online
Article
Text
id pubmed-9628213
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96282132022-11-03 Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis Yan, Jipeng Zhao, Jin Ning, Xiaoxuan Qin, Yunlong Xing, Yan Wang, Yuwei Jia, Qing Huang, Boyong Ma, Rui Lei, Changhui Zhou, Meilan Yu, Zixian Zhang, Yumeng Guo, Wei-Feng Sun, Shiren Front Immunol Immunology BACKGROUND: Emerging evidence revealed that gut microbial dysbiosis is implicated in the development of plasma cell dyscrasias and amyloid deposition diseases, but no data are available on the relationship between gut microbiota and immunoglobulin light chain (AL) amyloidosis. METHODS: To characterize the gut microbiota in patients with AL amyloidosis, we collected fecal samples from patients with AL amyloidosis (n=27) and age-, gender-, and BMI-matched healthy controls (n=27), and conducted 16S rRNA MiSeq sequencing and amplicon sequence variants (ASV)-based analysis. RESULTS: There were significant differences in gut microbial communities between the two groups. At the phylum level, the abundance of Actinobacteriota and Verrucomicrobiota was significantly higher, while Bacteroidota reduced remarkably in patients with AL amyloidosis. At the genus level, 17 genera, including Bifidobacterium, Akkermansia, and Streptococcus were enriched, while only 4 genera including Faecalibacterium, Tyzzerella, Pseudomonas, and Anaerostignum decreased evidently in patients with AL amyloidosis. Notably, 5 optimal ASV-based microbial markers were identified as the diagnostic model of AL amyloidosis and the AUC value of the train set and the test set was 0.8549 (95% CI 0.7310-0.9789) and 0.8025 (95% CI 0.5771-1), respectively. With a median follow-up of 19.0 months, further subgroup analysis also demonstrated some key gut microbial markers were related to disease severity, treatment response, and even prognosis of patients with AL amyloidosis. CONCLUSIONS: For the first time, we demonstrated the alterations of gut microbiota in AL amyloidosis and successfully established and validated the microbial-based diagnostic model, which boosted more studies about microbe-based strategies for diagnosis and treatment in patients with AL amyloidosis in the future. Frontiers Media S.A. 2022-10-19 /pmc/articles/PMC9628213/ /pubmed/36341382 http://dx.doi.org/10.3389/fimmu.2022.973760 Text en Copyright © 2022 Yan, Zhao, Ning, Qin, Xing, Wang, Jia, Huang, Ma, Lei, Zhou, Yu, Zhang, Guo and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yan, Jipeng
Zhao, Jin
Ning, Xiaoxuan
Qin, Yunlong
Xing, Yan
Wang, Yuwei
Jia, Qing
Huang, Boyong
Ma, Rui
Lei, Changhui
Zhou, Meilan
Yu, Zixian
Zhang, Yumeng
Guo, Wei-Feng
Sun, Shiren
Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
title Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
title_full Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
title_fullStr Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
title_full_unstemmed Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
title_short Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
title_sort alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628213/
https://www.ncbi.nlm.nih.gov/pubmed/36341382
http://dx.doi.org/10.3389/fimmu.2022.973760
work_keys_str_mv AT yanjipeng alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT zhaojin alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT ningxiaoxuan alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT qinyunlong alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT xingyan alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT wangyuwei alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT jiaqing alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT huangboyong alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT marui alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT leichanghui alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT zhoumeilan alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT yuzixian alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT zhangyumeng alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT guoweifeng alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis
AT sunshiren alterationsofthegutmicrobiotainpatientswithimmunoglobulinlightchainamyloidosis